AMGEN Inc
NASDAQ: AMGN
$307.81
+$18.79 (+6.5%)
Closing Price on February 5, 2025
AMGN Articles
Which well-known and large cap stocks to do the major analysts on Wall Street like for 2016? Here are 10.
Published:
Last Updated:
Goldman Sachs has seen many top stocks offering great rewards for 2016. The reason may be different for each, but these are what the wealthiest and most sophisticated investors have been told to buy.
Published:
Last Updated:
The short interest data are out for the December 15 settlement date, and short interest continued to be mixed in these selected biotech stocks.
Published:
Last Updated:
Here are four stocks that, while expensive at current levels, have fundamentals good enough to continue and even exceed their success in 2015 through next year.
Published:
Last Updated:
Biotech looks set to close out 2015 as its worst performing year since 2008. But can we expect a better 2016 for this exciting sector?
Published:
Last Updated:
Amgen is getting aggressive enough on its dividend payout that you might think the biotech giant is now just a Big Pharma stock.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous report, and short interest was mixed in these selected stocks for this settlement date.
Published:
Last Updated:
24/7 Wall St. has reviewed the short interest data on the top biotech companies.
Published:
Last Updated:
The short interest data are out for the October 30 settlement date, and short interest fell in selected biotech stocks.
Published:
Last Updated:
ThinkstockAmgen Inc. (NASDAQ: AMGN) released its third quarter earnings report Wednesday after the markets closed. The biotech giant had $2.72 in earnings per share (EPS) on $5.72 billion in revenue...
Published:
Last Updated:
Amgen is scheduled to report its third-quarter financial results after the markets close on Wednesday.
Published:
The October 15 short interest data have been compared with the previous figures, and short interest mixed in these selected biotech stocks.
Published:
Amgen is slowly getting closer to an FDA final decision for its first-of-a-kind cancer therapy, talimogene laherparepvec (T-Vec).
Published:
Cowen says the way to play biotech is with large cap sector leaders that can beat earnings estimates. It also thinks third-quarter earnings beats could highlight the risk of not owning biotech now.
Published:
The September 30 short interest data have been compared with the previous figures, and short interest increased in most of these selected biotech stocks for this settlement date.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.